Twist Bioscience Corporation (NASDAQ:TWST) Stock Has Consensus Price Target of $103.00 According to Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on Twist Bioscience, with eight buys, two holds and two sells; the average 12-month price target is $103, well below the stock’s recent $184.03 price.
• Twist reported quarterly revenue of $118.4 million, up 23.2% year over year, but missed the EPS estimate and remains unprofitable, with analysts expecting a full-year loss of $2.12 per share.
• The shares have surged near a 12-month high, while insiders sold substantial stock during the quarter—primarily to cover tax withholding on vested awards—potentially raising valuation and momentum concerns.

Shares of Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twelve research firms that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $103.00.

TWST has been the subject of several research reports. Robert W. Baird increased their price objective on shares of Twist Bioscience from $113.00 to $115.00 and gave the company an "outperform" rating in a research report on Tuesday, August 4th. Guggenheim restated a "buy" rating on shares of Twist Bioscience in a report on Monday, August 24th. Piper Sandler upped their target price on shares of Twist Bioscience from $85.00 to $115.00 and gave the company an "overweight" rating in a research report on Wednesday, August 5th. Leerink Partners increased their price target on shares of Twist Bioscience from $120.00 to $160.00 and gave the company an "outperform" rating in a report on Thursday, September 17th. Finally, UBS Group began coverage on Twist Bioscience in a research note on Wednesday, September 9th. They set a "neutral" rating and a $144.00 price objective on the stock.

Twist Bioscience Stock Performance

NASDAQ:TWST opened at $184.03 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. Twist Bioscience has a 1 year low of $23.30 and a 1 year high of $185.22. The stock's 50 day simple moving average is $125.11 and its two-hundred day simple moving average is $86.46. The company has a market cap of $11.54 billion, a price-to-earnings ratio of -82.90 and a beta of 2.22.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The firm had revenue of $118.38 million for the quarter, compared to analysts' expectations of $114.55 million. During the same period last year, the company earned $0.33 earnings per share. The firm's revenue was up 23.2% on a year-over-year basis. As a group, equities analysts anticipate that Twist Bioscience will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Emily Leproust sold 1,687 shares of the stock in a transaction on Monday, September 21st. The stock was sold at an average price of $165.49, for a total transaction of $279,181.63. Following the sale, the chief executive officer owned 618,902 shares in the company, valued at approximately $102,422,091.98. This represents a 0.27% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Adam Laponis sold 2,399 shares of the firm's stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $94.33, for a total value of $226,297.67. Following the completion of the sale, the chief financial officer owned 110,276 shares of the company's stock, valued at approximately $10,402,335.08. This represents a 2.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 516,574 shares of company stock valued at $77,493,635 over the last quarter. Company insiders own 3.08% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. E. Ohman J or Asset Management AB bought a new position in Twist Bioscience in the 2nd quarter valued at $853,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Twist Bioscience during the first quarter worth $22,563,000. Bank of America Corp DE boosted its stake in shares of Twist Bioscience by 46.3% during the first quarter. Bank of America Corp DE now owns 584,261 shares of the company's stock valued at $27,764,000 after purchasing an additional 184,907 shares during the period. William Blair Investment Management LLC purchased a new stake in shares of Twist Bioscience during the second quarter valued at $223,722,000. Finally, Deutsche Bank AG purchased a new stake in shares of Twist Bioscience during the second quarter valued at $9,265,000.

More Twist Bioscience News

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist’s partnership with Eli Lilly’s TuneLab AI-driven drug-discovery platform, under which Twist will serve as a preferred antibody-characterization data provider, strengthens its exposure to pharmaceutical research and artificial-intelligence applications. Twist Bioscience Expands AI Drug Discovery Exposure With Lilly TuneLab Partnership
• Positive Sentiment: The company’s latest quarterly results showed revenue of $118.4 million, up 23.2% year over year, while full-year revenue guidance was raised. Those results provide fundamental support for the recent rally, although Twist remains unprofitable and missed the latest quarterly EPS estimate.
• Neutral Sentiment: TWST recently reached a new 12-month high, making the shares vulnerable to consolidation as investors lock in gains after the partnership-driven advance. Twist Bioscience Hits New 12-Month High
• Neutral Sentiment: Reported short interest was listed at zero shares as of September 24, implying no measurable short-covering pressure. Because the figure conflicts with the article’s description of a “significant increase,” investors should treat the data cautiously.
• Negative Sentiment: CEO Emily Leproust sold 1,687 shares, while SVP Paula Green and insider Dennis Cho sold 294 and 348 shares, respectively, at about $165.49. The filings state the sales were intended to cover tax withholding on vested equity awards, and each executive retained a substantial position, reducing—but not eliminating—the negative signal. SEC insider transaction filings
• Negative Sentiment: Quiver data shows 87 insider sales and no purchases over the past six months. Combined with ongoing losses and a stock price well above many analyst targets, the pattern may weigh on momentum and valuation-sensitive investors.

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.